Endocrine resistance in breast cancer: gene expression profiling and modifications of the estrogen receptor

Kok, M-R.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons)

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
List of publications

In preparation

In preparation

Submitted

Under review

Under review


Microarray based determination of ER, PR and HER2 receptor status n breast cancer.

J Pathol. 2009; 218(3): 316-26

J Pathol. 2009; 217(3): 372-9

Continued on next page...
List of publications

Continued from previous page...


Thompson PM, Gotoh T, Kok M, White PS, Brodeur GM. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. *Oncogene* 2003; 22(7): 1002-11

Kok M, Bonfrer JM, Korse CM, de Jong D, Kersten MJ. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin’s lymphoma. *Tumorbiology* 2003; 24: 53-60